OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Core Insights - OXB has been recognized as a Champion in the 'Cell & Gene Therapy' category at the 2025 CDMO Leadership Awards Europe, reflecting its high performance based on feedback from biopharmaceutical professionals [1][2] - This recognition highlights OXB's excellence in quality, innovation, and service, coinciding with strong commercial momentum driven by increased demand for its CDMO services [2][3] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver life-changing therapies [4][5] - The company has 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies to provide expertise in various viral vector types [5][6] - OXB's capabilities range from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise [5][6] Technological Capabilities - OXB offers a wide range of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6] - The company utilizes advanced processes such as suspension and perfusion processes with process enhancers and stable producer and packaging cell lines [6] Industry Recognition - The CDMO Leadership Awards recognize organizations that excel in quality, capabilities, expertise, reliability, compatibility, and service, based on direct feedback from industry professionals [8]